Wellstat Biologics Corporation

Concordia Laboratories Inc.

University of Ottawa

Michael Scot Roberts

Robert Michael Lorence

Reid W Von Borstel

William S Groene

Harvey Rabin

John Cameron Bell

David F Stojdl

Brian D Lichty

Harold L Atkins

Conrad J Heilman, Jr

Robert M Lorence

Presently disclosed is a lighting system and methods of using the lighting system for in vitro potency assay for photofrin. The lighting system includes a lamp housing, a first lens, an infrared absorbing filter, an optical filter, and a second lens. The lamp housing includes a lamp and a light-port. In operation, broad spectrum light from the lamp exits the lamp housing by passing through the light-port. The first lens then collimates the broad spectrum light that exits the lamp housing through the light-port. The infrared absorbing filter then passes a first portion of the collimated broad spectrum light to the optical filter and absorbs infrared light of the broad spectrum light. The optical filter then passes a second portion of the collimated broad spectrum light to the second lens. The second lens then disperses the second portion of the collimated light to provide uniform irradiation of a cell culture plate. A method of using the lighting system for studying a photosensitizer is also disclosed.

Lighting systems and methods of using lighting systems for in vitro potency assay for Photofrin

Lighting systems and methods of using lighting systems for in virto potency assay for photofrin

Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. The treatment can also include administration of a monoclonal antibody against epidermal growth factor receptor, for example cetuximab.

Cancer treatment using viruses and camptothecins

Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin

The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.

Treatment of neoplasms with viruses

Infection and treatment of neoplasms with vesicular stomatitis virus

Treatment of neoplasms with RNA viruses

Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.

Cancer treatment using viruses, fluoropyrimidines and camptothecins

The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.

Purging of cells using viruses

Growing community of inventors

Myersville, MD, United States of America

Michael Scot Roberts